Compare Viatris Inc (VTRS) vs Exxon Mobil Corporation (XOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Viatris Inc vs Exxon Mobil Corporation — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while Exxon Mobil Corporation trades at $164.53 (market cap $660.62B). The key difference: Exxon Mobil Corporation is far larger — about 34.6× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.89%). Which is the better fit depends on your goals.
| VTRS | XOM | |
|---|---|---|
Market Cap | $19.09B | $660.62B |
Sector | Health | Energy |
52-Week High | $17.86 | $171.52 |
52-Week Low | $9.49 | $110.64 |
Enterprise Value | $31.21B | $692.40B |
Dividend Yield | 2.89% | 2.56% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.
The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.
ExxonMobil (XOM) trades at $164.26, up 3.01% today, with a neutral technical signal and bullish moving averages. The stock shows solid profitability with a 9.07% net margin and 12.55% ROE, though revenue and net income have declined from 2022 peaks. Recent earnings beat estimates in two of the last three quarters, with Q3 2026 results pending. Analyst consensus is a $168.14 price target, with 39% buy ratings. News highlights Exxon's Permian Basin strength and warnings of potential oil price spikes to $160.
XOM offers value with a P/E of 20.68 and strong cash flow, but faces risks from volatile oil prices and declining margins. The dividend provides income, yet geopolitical tensions and energy transition pressures pose challenges. Upside depends on execution in the Permian and oil market stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →About Exxon Mobil Corporation
Exxon Mobil Corporation operates petroleum and petro chemicals businesses. The Company provides operations include exploration and production of oil and gas, electric power generation, and coal and minerals operations. Exxon Mobil also manufactures and markets fuels, lubricants, and chemicals. Exxon Mobil serves customers worldwide.
Read more on XOM →
